Teligent Opens Product Development Lab in Estonia
News Oct 14, 2016
Teligent Inc has announced that it has opened a pharmaceutical Product Development laboratory in Estonia. The GMP-compliant lab will support the development of topical and injectable pharmaceutical products for the company's North American markets.
The 3,000-square foot facility also includes administrative space for quality assurance and supply chain employees who oversee the company's third-party contract manufacturing activities around the world.
"We are excited to strengthen our R&D capabilities through the opening of this product development lab in Estonia," commented Jason Grenfell-Gardner, President and CEO of the Company. "We are impressed by the caliber of scientific talent available in the country, and look forward to this lab working closely with our R&D colleagues in New Jersey.''
The Company established its operation in Estonia in 2015, where it has been managing logistics and supply relationships between third-party suppliers and the US and Canadian markets. Grenfell-Gardner concluded, ''The opening of this lab for analytical method and formulation work is the next step in our journey to build pharmaceutical capabilities in our Estonia business.''
Many life-saving medicines, including insulin, antibodies and vaccines, are derived from living cells. These “biologics” can be difficult to obtain and store on the battlefield or in remote areas. That’s why scientists are trying to develop portable systems that can quickly manufacture small batches of protein therapeutics on demand.READ MORE
18th International Conference on Pharmaceutics & Novel Drug Delivery Systems
May 27 - May 28, 2019